Bioventus Inc. (NASDAQ:BVS) Receives $14.00 Consensus PT from Analysts
by Jessica Moore · The Cerbat GemShares of Bioventus Inc. (NASDAQ:BVS – Get Free Report) have been assigned an average rating of “Buy” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $14.00.
A number of equities research analysts have issued reports on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bioventus in a research note on Monday, December 29th. Barrington Research increased their price target on Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, March 6th. Craig Hallum raised their price objective on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, March 6th. CJS Securities assumed coverage on Bioventus in a research report on Friday, March 27th. They set a “market outperform” rating and a $14.00 price objective for the company. Finally, Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th.
Get Our Latest Stock Report on BVS
Insider Buying and Selling at Bioventus
In other news, Director Michelle Mcmurry-Heath sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total transaction of $105,480.00. Following the completion of the transaction, the director owned 44,997 shares in the company, valued at $395,523.63. This trade represents a 21.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 33.00% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd grew its position in shares of Bioventus by 17,156.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after purchasing an additional 5,490 shares in the last quarter. Covestor Ltd grew its position in shares of Bioventus by 28.0% during the third quarter. Covestor Ltd now owns 9,951 shares of the company’s stock valued at $67,000 after purchasing an additional 2,176 shares in the last quarter. HB Wealth Management LLC purchased a new position in shares of Bioventus during the third quarter valued at about $72,000. Olympiad Research LP bought a new position in shares of Bioventus in the 3rd quarter valued at about $74,000. Finally, Prelude Capital Management LLC bought a new position in shares of Bioventus in the 3rd quarter valued at about $74,000. Hedge funds and other institutional investors own 62.94% of the company’s stock.
Bioventus Trading Up 3.4%
Shares of BVS stock opened at $9.14 on Monday. Bioventus has a 52-week low of $5.81 and a 52-week high of $9.53. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.19 and a current ratio of 1.70. The firm has a market capitalization of $759.99 million, a PE ratio of 27.70 and a beta of 0.70. The stock has a fifty day simple moving average of $8.67 and a two-hundred day simple moving average of $7.78.
Bioventus (NASDAQ:BVS – Get Free Report) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.02. Bioventus had a return on equity of 28.88% and a net margin of 4.00%.The business had revenue of $157.90 million during the quarter. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.
Bioventus Company Profile
Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.